The first evidence of the association of NOS3 polymorphisms with circulating tumor cells was demonstrated between the intron 4 polymorphism and the folate hydrolase – prostate-specific membrane antigen (FOLH1) expression in the peripheral blood [23]. The gene discussed is FOLH1; the disease is neoplasm.